MD Conference Express ESC 2012 - (Page 1) Peer-Reviewed CARDIOLOGY Clinical Trial Highlights THE OFFICIAL PEER-REVIEWED HIGHLIGHTS FROM THE Translational Research 25 - 29 August, 2012 Munich, Germany Therapeutic Updates TAVI: 10 Years after the First Case The first human transcatheter aortic valve implantation (TAVI) was performed in 2002. Since then, TAVI has been evaluated as an alternative to surgical aortic valve replacement and medical treatment in several clinical trials. Steven Windecker, MD, Bern University Hospital, Bern, Switzerland, reviewed the evidence from these trials. See page 9. Distribution of this independent report is supported by ALSO IN THIS ISSUE • 2012 ESC Guidelines Overview • Clinical Trial Highlights – The Science Behind Cardiology • New Treatment Approaches for Hypertension http://www.mdconferencexpress.com http://www.escardio.org Table of Contents for the Digital Edition of MD Conference Express ESC 2012 MD Conference Express ESC 2012 Contents ESC 2012 Clinical Practice Guidelines TAVI: 10 Years After the First Case PARAMOUNT Trial Results TRILOGY ACS Outcomes Results from the ALTITUDE Trial Results of the WOEST Trial Results from the Aldo-DHF Trial FAME 2 Results Results from the IABP-SHOCK II Trial STEMI Mortality Decreases in France While Some Key Risk Factors Increase Results from the PURE Study PURE: Treatment and Control of Hypertension Genetic Determinants of Variability in Dabigatran Exposure The RE-LY AF Registry TRA 2°P-TIMI 50 Results Rivaroxaban of Benefit in STEMI: ATLAS ACS 2-TIMI 51 Ivabradine Effect on Recurrent Hospitalization for HF CLARIFY: Similar 1-Year Outcomes for Men and Women with Stable CAD HPS2-THRIVE Study Results PRoFESS Study Results Outcomes from the CARDia Trial Hypertension Atrial Fibrillation Heart Failure MD Conference Express ESC 2012 http://www.nxtbook.com/nxtbooks/md_conference_express/esc2012 http://www.nxtbookMEDIA.com